

AccuVert™ HIV-1 Seroconversion Panel 0600-0252 (PRB970)

INTENDED USE

The AccuVert™ HIV-1 Seroconversion Panel 0600-0252 (PRB970) is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostics manufacturers and clinical laboratories to evaluate their HIV-1 test systems using well-characterized specimens, and to provide comprehensive data for comparative analysis. For Research Use Only. Not for use in diagnostic procedures.

PRODUCT DESCRIPTION

This product consists of a set of four undiluted plasma samples from a single plasma donor collected during a period of HIV-1 seroconversion. All units were maintained frozen, except for the interval of dispensing into vials. No preservatives were added.

Item No. 0600-0252 1 vial per member

4 members, 1.0 mL per vial

STORAGE

Panel members should be stored frozen at -70°C or colder to preserve HIV-1 RNA. HIV antibody and antigen will be preserved at -20°C or colder. LGC SeraCare recommends that the panel members be divided into smaller aliquots, if appropriate, to avoid multiple freeze-thaw cycles. If turbidity or particulate matter is observed, the samples should be centrifuged in accordance with each test kit manufacturer's instructions for sample preparation.

INTERPRETATION OF RESULTS

The data sheet for AccuVert HIV-1 Seroconversion Panel 0600-0252 (PRB970) is available at www.seracare.com. The data sheet lists results for panel members generated using commercially available screening, monitoring and confirmatory tests approved in the U.S. and/or the European Union. The tests that are listed were performed at SeraCare or at recognized reference laboratories (RL) by individuals who routinely use these procedures. Information regarding specific test methods is available on the data sheet. Data Sheets are updated when new data are available.

LIMITATIONS

The AccuVert HIV-1 Seroconversion Panel 0600-0252 (PRB970) is offered for research use only. Not for use in diagnostic procedures. Data are provided for informational purposes. LGC SeraCare Life Sciences does not claim that others can duplicate test results exactly.

PRECAUTIONS

These materials have not been treated and should be considered biohazardous. Follow Universal Precautions¹. Some panel members were found positive by tests for HIV markers including HIV-1 RNA, HIV-1 antigen and anti-HIV. The units that make up this panel were found negative for anti-HCV and HBsAg. This does not ensure the absence of these or other human pathogens.

Do not pipette by mouth. Do not smoke, eat, or drink in areas where specimens are handled.

These materials should be disposed of in a manner that will inactivate pathogenic agents.

REFERENCES

 Siegel JD, Rhinehart E, Jackson M, Chiarello L, and the Healthcare Infection Control Practices Advisory Committee, 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings.

For assistance, contact LGC SeraCare at 508.244.6400.

The package insert for this panel can be found at www.seracare.com.

A printed copy of the package insert or data sheet may be requested by email at CDx-Info@LGCGroup.com or by phone at 508.244.6400.

508.244.6400 • 800.676.1881 Toll Free • 508.634.3334 Fax www.seracare.com

Page **1** of **1** 12181-04 February 2022